Skip to content

Patrick MacDonald Fisher

4 papers in the library · 61 citations · publishing 2022-2024

Papers

Sort Most recent Most cited

Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms.

Neuroscience Applied 2024 Drummond E-Wen Mcculloch, Juan Pablo Lopez, Christina Dalla et al. 2 citations

Classical psychedelic drugs, e.g., psilocybin and LSD, stimulate the serotonin 2A receptor (5-HT2AR) and have recently been intensely investigated for their clinical effects in various brain disorders. At the ECNP "New Frontiers meeting" in March 2023, scientific experts in psychedelics met to identify key knowledge gaps in the mechanism of action of psychedelics as investigated using...

DOI: 10.1016/j.nsa.2023.103929 (opens in new tab) Full text (opens in new tab) Hallucinogen investigation Psychoactive drug research Entheogen research Psychedelic compounds +15

Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation.

Comprehensive psychoneuroendocrinology February 1, 2023 Daniel Rødbro Burmester, Martin Korsbak Madsen, Attila Szabo et al. 24 citations

Psilocybin is a serotonergic psychedelic that has gained prominent attention recently as a potential therapeutic for neuropsychiatric disorders including Major Depressive Disorder. Pre-clinical and initial studies in humans suggest that serotonin 2A receptor agonists, including serotonergic psychedelics, have anti-inflammatory effects. This may contribute to its therapeutic effects as previous...

DOI: 10.1016/j.cpnec.2022.100163 (opens in new tab) Full text (opens in new tab) Psychedelic mushrooms Immune system Neuroinflammation Psychedelics +7

Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial)

BMJ Open October 1, 2022 Mathias Ebbesen Jensen, Dea Siggaard Stenbæk, Tobias Søgaard Juul et al. 21 citations

Introduction Alcohol use disorder is a difficult-to-treat psychiatric disorder and a major burden on public health. Existing treatment efficacy is moderate, and relapse rates are high. Preliminary findings suggest that psilocybin, a psychedelic compound, can safely and reliably occasion highly meaningful experiences that may spur a positive change in drinking behaviour when administered in a...

DOI: 10.1136/bmjopen-2022-066019 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Clinical trials Substance misuse Addiction treatment +3

Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses.

Neuroscience and Biobehavioral Reviews July 1, 2022 Drummond E-Wen Mcculloch, Gitte Moos Knudsen, Frederick Streeter Barrett et al. 14 citations

Clinical research into serotonergic psychedelics is expanding rapidly, showing promising efficacy across myriad disorders. Resting-state functional magnetic resonance imaging (rs-fMRI) is a commonly used strategy to identify psychedelic-induced changes in neural pathways in clinical and healthy populations. Here we, a large group of psychedelic imaging researchers, review the 42 research...

DOI: 10.1016/j.neubiorev.2022.104689 (opens in new tab) Full text (opens in new tab) DMT LSD Psilocin Psilocybin +10